Brief: Yuyu Pharma Announces First Patient Enrolled In Phase 2 Study Evaluating YP-P10 Ophthalmic Solution
20/07/2022 19:04
July 20 (Reuters) - Yuyu Pharma Inc 000220.KS :
* YUYU PHARMA ANNOUNCES FIRST PATIENT ENROLLED IN PHASE 2
CLINICAL
STUDY EVALUATING YP-P10 OPHTHALMIC SOLUTION FOR THE TREATMENT OF
DRY EYE DISEASE
Source text for Eikon: ID:nPn3ksBlya
Further company coverage: 000220.KS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Yuyu Pharma
See all newsBrief: Yuyu Pharma Announces Strategic Investment In Dalan Animal Health As Part Of Accelerated Global Expansion In Animal Health
Brief: Yuyu Pharma To Acquire 2 Billion Won Worth Of Own Shares
Brief: Yuyu Pharma Inc Wins 122 Billion Won Order
Brief: Yuyu Pharma To Cancel 1.4 Billion Won Worth Of Own Shares
Brief: Yuyu Pharma Announces First Patient Enrolled In Phase 2 Study Evaluating YP-P10 Ophthalmic Solution